SCHEMBL6344778

SCHEMBL6344778

Fc1cccc2nc3c(cnn3-c3ccccn3)c(Cl)c12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.40
CYP17A1 P05093 2/20 0.39
DPP4 P27487 1/20 0.39
CYP1A2 P05177 1/20 0.37
OXTR P30559 1/20 0.36
RAB9A P51151 1/20 0.36
GSK3B P49841 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
IRAK4 Q9NWZ3 2/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
PTK2 Q05397 1/20 0.35
SLC2A1 P11166 1/20 0.35
SLC2A2 P11168 1/20 0.35
SLC2A3 P11169 1/20 0.35
HSD17B10 Q99714 1/20 0.34
AURKA O14965 1/20 0.34
FLT3 P36888 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6344817 0.83 MAOA (0.46) CYP17A1DPP4CYP1A2RAB9AGSK3B
SCHEMBL6340222 0.83 CYP17A1 (0.39) SCN9ACYP17A1DPP4CYP1A2OXTR
SCHEMBL6340237 0.80 DPP4 (0.41) CYP17A1DPP4CYP1A2GSK3BFFAR4
SCHEMBL6344329 0.79 ALDH1A1 (0.41) RAB9AIRAK4ALDH1A1HPGDHSD17B10
SCHEMBL6341846 0.77 DPP4 (0.42) CYP17A1DPP4CYP1A2OXTRGSK3B
SCHEMBL6340010 0.73 SLC2A1 (0.46) DPP4RAB9AIRAK4ALDH1A1SLC2A1
SCHEMBL18367192 0.72 CYP17A1 (0.44) CYP17A1DPP4CYP1A2OXTRRAB9A
SCHEMBL30587545 0.72 CYP17A1 (0.44) CYP17A1DPP4CYP1A2OXTRRAB9A
Hydrochloric Acid SCHEMBL6341859 0.72 RAB9A (0.47) CYP17A1DPP4CYP1A2RAB9AGSK3B
SCHEMBL6351194 0.71 SLC2A1 (0.48) CYP17A1DPP4CYP1A2RAB9AIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949648-B2 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-09-27 US disclosed
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1270572-A1 CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof PTGS1, PTGIS, IL5 SCN9A 4356/4885CYP17A1 477/4885DPP4 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.